Circulating Markers for Ischemic Heart Disease
2 other identifiers
observational
550
1 country
1
Brief Summary
The purpose of this research is to determine if two proteins in the blood are increased during acute myocardial infarction and whether their levels are higher in those who develop heart failure than those who do not. These two proteins are produced and potentially released when the heart muscle is damaged. They may then be released into the blood and be detected by standard method in the research laboratory. At this time, detection of an increase in these proteins in the blood is not known to be associated with any disease or myocardial infarction.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2007
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2007
CompletedFirst Submitted
Initial submission to the registry
September 26, 2008
CompletedFirst Posted
Study publicly available on registry
September 30, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 1, 2027
August 12, 2025
July 1, 2025
19.8 years
September 26, 2008
August 10, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Hospitalization for acute myocardial infarction, stroke or death
3 years
Study Arms (1)
Myocardial Infarction
Eligibility Criteria
There are two arms to this study: The investigators hope to enroll 350 healthy individuals, as defined by having no prior diagnosis of heart disease to determine baseline levels and diurnal variations of the markers. Participants being evaluated for an acute Myocardial Infarction as determined by positive CK MB/troponin levels, will be asked to enroll.
You may qualify if:
- men and women, 18 years of age and over with acute myocardial infarction (determined by positive cardiac markers -CKMB/ troponin) with or without heart failure (dyspnea, rales, edema, elevated jugular venous pressure, ascites).
- Heart failure can be diagnosed using imaging evidence such as dilated heart, poor contractile function or echocardiographic Doppler evidence of diastolic dysfunction or elevated right- or left-sided filling pressures
- A control group of male subjects age 60 and older without history of MI or heart disease
You may not qualify if:
- Subjects unable to give consent
- Subjects who have undergone cardiac or non-cardiac surgery in the 3 months prior to enrollment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- UConn Healthlead
Study Sites (1)
University of Connecticut Health Center
Farmington, Connecticut, 06030, United States
Biospecimen
serum
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Bruce T. Liang, MD
UConn Health
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Medicine, Director Pat and Jim Calhoun Cardiovascular Center
Study Record Dates
First Submitted
September 26, 2008
First Posted
September 30, 2008
Study Start
June 1, 2007
Primary Completion (Estimated)
March 1, 2027
Study Completion (Estimated)
March 1, 2027
Last Updated
August 12, 2025
Record last verified: 2025-07